Cargando…
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
BACKGROUND: Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of non-adherence and impact of non-adherence on treatment response in adults with attentio...
Autores principales: | Kooij, J J Sandra, Rösler, Michael, Philipsen, Alexandra, Wächter, Sandra, Dejonckheere, Joachim, van der Kolk, Annemarie, van Agthoven, Michel, Schäuble, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577504/ https://www.ncbi.nlm.nih.gov/pubmed/23347693 http://dx.doi.org/10.1186/1471-244X-13-36 |
Ejemplares similares
-
Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
por: Buitelaar, J. K., et al.
Publicado: (2012) -
Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
por: Buitelaar, Jan K, et al.
Publicado: (2009) -
The effect of methylphenidate-OROS(®) on the narrative ability of children with attention-deficit hyperactivity disorder
por: Rausch, Tessa L., et al.
Publicado: (2017) -
Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder
por: Chou, Wen-Jiun, et al.
Publicado: (2018) -
Methylphenidate use in children with attention deficit hyperactivity disorder
por: Machado, Felipe Salles Neves, et al.
Publicado: (2015)